BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. GlobeNewswire August 13, 2025 CARSON CITY, Nev., Aug. […]

Noodles & Company Announces Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 BROOMFIELD, Colo., Aug. 13, 2025 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 1, 2025. Key highlights for the second quarter of 2025 versus the second quarter of 2024 include: Total revenue

HeartCore Reports Financial Results for Second Quarter and Six Months Ended June 30, 2025 GlobeNewswire August 13, 2025 NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter

Roadzen Reports Best Fiscal Q1 in Company History with 22% Revenue Growth, 92% Lower Net Loss, and 50% Adjusted EBITDA Improvement Over the Same Quarter Last Year GlobeNewswire August 13, 2025 1. Record Fiscal Q1 Revenue Sets Stage for the Year AheadFirst quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire August 13, 2025 – Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance – – Exceptional 94% overall survival (OS) observed at

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update GlobeNewswire August 13, 2025 Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion vs. Observation More than 50

Codexis Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis(R) platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif.,

Expion360 Reports Second Quarter 2025 Financial and Operational Results GlobeNewswire August 13, 2025 Q2 2025 Sales Growth of 134% to $3.0 Million Fueled by Strong Demand for New Products and Technologies Records Two of the Most Successful Months of Sales in Company History in Q2 2025 Sixth Consecutive Quarter of Sales Growth REDMOND, Ore., Aug.

Longeveron(R) Announces Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire August 13, 2025 Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the third quarter of 2026,

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 13, 2025 Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the third quarter of 2025,